Clinical Trial: A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07633470) titled 'A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)' on May 19.

Brief Summary: The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl(R) over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Alzheimer Disease

Intervention: DRUG: Zunveyl(R)

Zunveyl(R) delayed release oral tablets.

Recruitment Status: RECRUITING

Sponsor: Alpha Cognition, Inc

Published by HT Digital Content Services with permission from Health Daily Di...